CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
CYTOKINETICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$62.65+0.70 (+1.13%)
Close on Oct 19, 2026
- Market cap
- $8.28M
- P/E (TTM)
- –
- Dividend yield
- –
CYTOKINETICS INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| License and Milestone Revenues [Member] | $79.35M | $15.00M | $3.50M | $1.00M | $54.90M | – | – | – | – | 90.1% | +429.0% |
| Collaboration Revenues [Member] | $8.69M | $3.47M | $4.03M | $6.59M | – | – | – | – | – | 9.9% | +150.0% |
| License Revenues [Member] | – | – | $0 | $0 | $54.90M | $36.50M | $0 | $5.13M | $8.80M | – | – |
| Research and Development Revenue [Member] | – | – | – | – | – | – | – | $26.37M | $4.57M | – | – |
| Research and Development Revenues [Member] | – | – | $4.03M | $6.59M | $10.57M | $16.53M | $26.87M | $26.37M | – | – | – |
| Milestone Revenues [Member] | – | – | $3.50M | $1.00M | $5.00M | $2.80M | $0 | $0 | – | – | – |
| Milestone Revenues [Member] | – | – | – | – | – | $2.50M | – | – | – | – | – |
| Realization of Revenue Participation Right Purchase Agreement [Member] | – | $0 | $0 | $87.00M | $0 | $0 | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Cytokinetics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.